Shares of biotechnology company SCYNEXIS (NASDAQ:SCYX) have skyrocketed today after it announced an exclusive licensing deal with GlaxoSmithKline (NYSE:GSK) for brexafemme.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,